Metaphore Pharmaceuticals, Inc. to Host Conference Call Following Presentation at CIBC World Markets Conference
Company to Discuss New Phase II Clinical Trial Data
FT. LEE, N.J., April 26 /PRNewswire/ -- Metaphore Pharmaceuticals, Inc.
will host a conference call at 11:00 a.m. ET Tuesday, April 27, 2004 to
discuss new clinical data from the Phase II study of the company's lead drug
candidate, M40403. The conference call will follow the company's webcast
presentation of the Phase II data at the CIBC World Markets Annual
Biotechnology and Specialty Pharmaceuticals Conference.
President and Chief Executive Officer Alan W. Dunton, M.D. and Senior Vice
President, Clinical Development Robert A. Medve, M.D. will review results of
the 350-patient pain study, conducted in Austin, Texas and Baltimore,
Maryland, comparing the analgesic effects and safety of M40403 and morphine to
morphine alone.
To participate in the conference call, please dial (800) 279-9534
(domestic) or (719) 457-2685 (international). A replay of the call will be
available for one week by dialing (888) 203-1112 (domestic) or (719) 457-0820
(international) and entering passcode 431421.
More about the Company
Metaphore Pharmaceuticals is a privately held biotechnology company which
discovers, develops and will market drugs that prevent and treat
inflammatory/autoimmune diseases and disorders, and pain. The company
leverages its expertise in chemistry and biology to discover and develop small
molecule compounds that mimic the activity of human enzymes. Metaphore's lead
compounds mimic the function of superoxide dismutase (SOD), a beneficial
enzyme that serves an important protective role in the body by removing
superoxide, a toxic free radical that can damage cells and tissues.
Superoxide anions are implicated in a variety of diseases associated with pain
and inflammation.
Metaphore has a global, multilayered intellectual property estate covering
its broad class of compounds including composition of matter and use patents.
This IP estate includes 31 issued and 39 pending worldwide patents.
Product candidates in U.S. clinical testing have broad therapeutic
potential across a variety of diseases. Metaphore currently focuses its
clinical development efforts in pain, rheumatoid arthritis and inflammatory
disorders. These markets are significant in terms of scope and size. The
company maintains offices in Fort Lee, New Jersey and St. Louis, Missouri. For
more information on Metaphore, please visit the Web site at:
metaphore.com. |
